secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001193125-23-234395
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal appoints Bill Sibold as President & CEO, effective Sept 8, 2023
------------------------------------------------------------------------

- Bill Sibold appointed President & CEO effective Sept 8, 2023; also joins Board as Class II director.
- Sibold compensation: $875k base salary, 75% target bonus, $520k sign-on cash, 50k time-based RSUs, 50k performance PSUs.
- Former CEO Paul Friedman steps down but remains on Board; receives 12 months base salary plus 100% of target bonus.
- Sibold previously EVP Specialty Care at Sanofi; prior roles at Biogen, Avanir. Yale BA, Harvard MBA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/0001193125-23-234395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/d444513d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-234395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer